Experienced in Telangiectasia

Dr. Melody L. Stone

Dermatology
Melody L Stone MD PA
300 Pershing Ave, 
Shenandoah, IA 
Accepting New Patients
Experienced in Telangiectasia
Melody L Stone MD PA
300 Pershing Ave, 
Shenandoah, IA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Melody Stone is a Dermatologist in Shenandoah, Iowa. Dr. Stone is rated as an Experienced provider by MediFind in the treatment of Telangiectasia. Her top areas of expertise are Actinic Keratosis, Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, and Warts. Dr. Stone is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in MO
Hospital Affiliations
Harrison County Community Hospital
Shenandoah Medical Center
Mosaic Life Care At St Joseph
Clarinda Regional Health Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 12 Less Insurance Carriers -

Locations

MELODY L STONE MD PA
300 Pershing Ave, Shenandoah, IA 51601
Other Locations
MELODY L STONE MD PA
1419 Village Dr, Saint Joseph, MO 64506
MELODY L STONE MD PA
700 Oregon St, Hiawatha, KS 66434

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: December 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

1 Total Publications

Vilobelimab to improve clinical outcomes of moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: Results of the SHINE double-blind, placebo-controlled randomised trial.
Vilobelimab to improve clinical outcomes of moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: Results of the SHINE double-blind, placebo-controlled randomised trial.
Journal: The British journal of dermatology
Published: February 02, 2025
Similar Doctors
Distinguished in Telangiectasia
Dr. Christopher Huerter
Dermatology
Distinguished in Telangiectasia
Dr. Christopher Huerter
Dermatology

Alegent Creighton Clinic

7710 Mercy Rd, Suite 3000, 
Omaha, NE 
 (48.2 miles away)
402-343-8650
Languages Spoken:
English
See accepted insurances

Christopher Huerter is a Dermatologist in Omaha, Nebraska. Dr. Huerter is rated as a Distinguished provider by MediFind in the treatment of Telangiectasia. His top areas of expertise are Actinic Keratosis, Autoerythrocyte Sensitivity, Gardner-Diamond Syndrome, and Psoriasis.

Distinguished in Telangiectasia
Dr. Scott M. Debates
Dermatology
Distinguished in Telangiectasia
Dr. Scott M. Debates
Dermatology

Physicians Clinic Inc

515 N 162nd Ave, 
Omaha, NE 
 (54.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Debates is a Dermatologist in Omaha, Nebraska. Dr. Debates is rated as a Distinguished provider by MediFind in the treatment of Telangiectasia. His top areas of expertise are Actinic Keratosis, Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, and Seborrheic Keratosis. Dr. Debates is currently accepting new patients.

Advanced in Telangiectasia
Dr. Ashley L. Drake
Dermatology
Advanced in Telangiectasia
Dr. Ashley L. Drake
Dermatology

Dermatology Specialists Of Omaha LLC

909 N 96th St, Suite 201, 
Omaha, NE 
 (50.7 miles away)
402-330-4555
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ashley Drake is a Dermatologist in Omaha, Nebraska. Dr. Drake is rated as a Distinguished provider by MediFind in the treatment of Telangiectasia. Her top areas of expertise are Neurocutaneous Melanosis, Giant Congenital Melanocytic Nevus, Familial Atypical Multiple Mole Melanoma Syndrome, and Giant Congenital Nevus. Dr. Drake is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stone's expertise for a condition
ConditionClose
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile